SAB BiotherapeuticsSABS -1.03%26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, SAB Biotherapeutics ranks worse than 105820% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SAB Biotherapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-18.05 Mil. SAB Biotherapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, SAB Biotherapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
SAB Biotherapeutics (NAS:SABS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SAB Biotherapeutics EBITDA Margin % Related Terms
SAB Biotherapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SAB Biotherapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SABS vs TRDA, ACIU, AVXL: EBITDA Margin % Comparison
For the Biotechnology subindustry, SAB Biotherapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (SABS) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SAB Biotherapeutics and its competitors. According to the industry distribution chart, SAB Biotherapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is SAB Biotherapeutics' EBITDA Margin % too high?
SAB Biotherapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, SAB Biotherapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' EBITDA Margin % compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places SAB Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score
Get the complete analysis for SABS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
